UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Comparison of acquired activated protein C resistance, using the CAT and ST-genesia® analysers and three thrombin generation methods, in APS and SLE patients

Efthymiou, M; Lane, PJ; Isenberg, D; Cohen, H; Mackie, IJ; (2022) Comparison of acquired activated protein C resistance, using the CAT and ST-genesia® analysers and three thrombin generation methods, in APS and SLE patients. Journal of Clinical Medicine , 11 (1) , Article 69. 10.3390/jcm11010069. Green open access

[thumbnail of jcm-11-00069-v2.pdf]
Preview
Text
jcm-11-00069-v2.pdf - Published Version

Download (2MB) | Preview

Abstract

Background: Acquired activated protein C resistance (APCr) has been identified in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). Objective: To assess agreement between the ST-Genesia® and CAT analysers in identifying APCr prevalence in APS/SLE patients, using three thrombin generation (TG) methods. Methods: APCr was assessed with the ST- Genesia using STG-ThromboScreen and with the CAT using recombinant human activated protein C and Protac® in 105 APS, 53 SLE patients and 36 thrombotic controls. Agreement was expressed in % and by Cohenʹs kappa coefficient. Results: APCr values were consistently lower with the ST- Genesia® compared to the CAT, using either method, in both APS and SLE patients. Agreement between the two analysers in identifying APS and SLE patients with APCr was poor (≤65.9%, ≤0.20) or fair (≤68.5%, ≥0.29), regardless of TG method, respectively; no agreement was observed in thrombotic controls. APCr with both the ST Genesia and the CAT using Protac®, but not the CAT using rhAPC, was significantly greater in triple antiphospholipid antibody (aPL) APS patients compared to double/single aPL patients (p <0.04) and in thrombotic SLE patients compared to non-thrombotic SLE patients (p < 0.05). Notably, the ST-Genesia®, unlike the CAT, with either method, identified significantly greater APCr in pregnancy morbidity (median, confidence intervals; 36.9%, 21.9–49.0%) compared to thrombotic (45.7%, 39.6–55.5%) APS patients (p = 0.03). Conclusion: Despite the broadly similar methodology used by CAT and ST-Genesia®, agreement in APCr was poor/fair, with results not being interchangeable. This may reflect differences in the TG method, use of different reagents, and analyser data handling.

Type: Article
Title: Comparison of acquired activated protein C resistance, using the CAT and ST-genesia® analysers and three thrombin generation methods, in APS and SLE patients
Open access status: An open access version is available from UCL Discovery
DOI: 10.3390/jcm11010069
Publisher version: https://doi.org/10.3390/jcm11010069
Language: English
Additional information: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Keywords: antiphospholipid syndrome; systemic lupus erythematosus; blood coagulation test; activated protein C resistance; thrombomodulin; activated protein C
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10141705
Downloads since deposit
7Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item